- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00716807
Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain
May 19, 2016 updated by: University of California, San Francisco
Modeling Kappa Opioid Analgesic Mechanisms in Chronic Orofacial Pain Disorders
Patients with chronic masticatory muscle pain (i.e., pain greater than three months) or patients with burning mouth syndrome participate in this study.
The aim of the study is to compare the pain killing effectiveness of nalbuphine, a narcotic pain killer, administered with either placebo or naloxone, a drug used to treat opiate overdose.
A second goal is to determine if there are sex differences in these two drug regimens.
Drugs will be administered with single-use intranasal spray devices.
All participants will receive two sprays (one spray per nostril).
One of the two sprays will be nalbuphine (5 mg).
The other spray will be naloxone in half the participants and placebo in the other half.
Study Overview
Status
Terminated
Study Type
Interventional
Enrollment (Actual)
46
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinical diagnosis of temporomandibular muscle pain OR
- Clinical diagnosis of burning mouth syndrome
- Pain duration: at least 3 months
- Pain severity: 2 or greater on a 0 - 10 scale
Exclusion Criteria:
- No adverse reaction to study drugs
- Not currently using narcotic analgesic drugs
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: TMD 1
|
Patient group: temporomandibular disorders.
Nalbuphine 5 mg administered by nasal spray (one time only).
Naloxone 0.4 mg administered by nasal spray (one time only).
Patient group: burning mouth syndrome.
Nalbuphine 5 mg administered by nasal spray (one time only).
Naloxone 0.4 mg administered by nasal spray (one time only).
|
PLACEBO_COMPARATOR: TMD 2
|
Patient group: temporomandibular disorders.
Nalbuphine 5 mg administered by nasal spray (one time only).
Placebo (naloxone vehicle) administered by nasal spray (one time only).
Patient group: Burning mouth syndrome.
Nalbuphine 5 mg administered by nasal spray (one time only).
Placebo (naloxone vehicle) administered by nasal spray (one time only).
|
EXPERIMENTAL: BMS 1
|
Patient group: temporomandibular disorders.
Nalbuphine 5 mg administered by nasal spray (one time only).
Naloxone 0.4 mg administered by nasal spray (one time only).
Patient group: burning mouth syndrome.
Nalbuphine 5 mg administered by nasal spray (one time only).
Naloxone 0.4 mg administered by nasal spray (one time only).
|
PLACEBO_COMPARATOR: BMS 2
|
Patient group: temporomandibular disorders.
Nalbuphine 5 mg administered by nasal spray (one time only).
Placebo (naloxone vehicle) administered by nasal spray (one time only).
Patient group: Burning mouth syndrome.
Nalbuphine 5 mg administered by nasal spray (one time only).
Placebo (naloxone vehicle) administered by nasal spray (one time only).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pain Intensity as Measured on a Visual Analogue Scale (VAS) Ranging From Zero to 100.
Time Frame: 20 minute intervals for three hours.
|
20 minute intervals for three hours.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (ACTUAL)
June 1, 2010
Study Completion (ACTUAL)
June 1, 2010
Study Registration Dates
First Submitted
July 14, 2008
First Submitted That Met QC Criteria
July 15, 2008
First Posted (ESTIMATE)
July 16, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
May 20, 2016
Last Update Submitted That Met QC Criteria
May 19, 2016
Last Verified
October 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Pain
- Neurologic Manifestations
- Disease
- Musculoskeletal Diseases
- Muscular Diseases
- Stomatognathic Diseases
- Mouth Diseases
- Jaw Diseases
- Craniomandibular Disorders
- Mandibular Diseases
- Myofascial Pain Syndromes
- Syndrome
- Joint Diseases
- Temporomandibular Joint Disorders
- Temporomandibular Joint Dysfunction Syndrome
- Facial Pain
- Burning Mouth Syndrome
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Narcotic Antagonists
- Naloxone
- Nalbuphine
Other Study ID Numbers
- NIH/NIDCR R01 DE018526-1
- 1R01DE018526-01 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Temporomandibular Joint Dysfunction Syndrome
-
Yuzuncu Yıl UniversityCompletedComparative Evaluation of the Effectiveness of Diclofenac Sodium Versus Vitamin D on Myofascial PainMyofascial Pain Dysfunction Syndrome,Temporomandibular JointTurkey
-
Riphah International UniversityCompletedTemporomandibular Joint Dysfunction | Temporomandibular JointPakistan
-
Jagiellonian UniversityCompletedTemporomandibular DisordersPoland
-
University of Nove de JulhoCompletedPhotobiomodulation In the Masseter and Temporal In Patients With Temporomandibular Joint DysfunctionTemporomandibular Disorder
-
Jagiellonian UniversityCompletedTEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME
-
University of ValenciaCompletedTemporomandibular Dysfunction (TMD)Spain
-
Jaseng Medical FoundationCompletedTemporomandibular DisorderKorea, Republic of
-
Copka SonpashanNot yet recruitingTemporomandibular Joint Dysfunction
-
Istanbul Gelisim UniversityRecruitingTemporomandibular Joint DisordersTurkey
-
Bahçeşehir UniversityCompletedTemporomandibular Joint DysfunctionTurkey
Clinical Trials on nalbuphine plus naloxone
-
University of California, San FranciscoTerminated
-
Assiut UniversityCompleted
-
Abdelrady S Ibrahim, MDCompleted
-
Trevi TherapeuticsCompletedPrurigo Nodularis | Prurigo | Nodularis PrurigoGermany
-
Trevi TherapeuticsSyneos HealthUnknownHepatic Impairment | NalbuphineUnited States
-
Mansoura UniversityCompletedUpper Extremity TraumaEgypt
-
Trevi TherapeuticsCompletedPruritus | Uremic PruritusUnited States
-
Trevi TherapeuticsRecruitingIdiopathic Pulmonary FibrosisUnited Kingdom, Australia, Netherlands, Italy, Spain, Poland, Turkey, Canada, Chile, Germany
-
Assiut UniversityCompleted
-
Trevi TherapeuticsCompletedPruritus | Uremic PruritusUnited States, Poland, Romania